quinazolines has been researched along with saracatinib in 160 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (13.13) | 29.6817 |
| 2010's | 114 (71.25) | 24.3611 |
| 2020's | 25 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Gautschi, O; Lee, D | 1 |
| Allen, J; Breed, J; Costello, G; Curwen, J; Fennell, M; Green, TP; Hennequin, LF; Lambert-van der Brempt, C; Morgentin, R; Norman, RA; Olivier, A; Otterbein, L; Plé, PA; Warin, N | 1 |
| Anderson, E; Beyer, AR; Cui, Y; Fuqua, SA; Green, TP; Herynk, MH; Weiss, H | 1 |
| Clack, G; Dixon, JM; Elvin, P; Fennell, M; Green, TP; Jacobs, V; Jones, RJ; Marshall, A; Renshaw, L; Womack, C; Young, O | 1 |
| Green, TP; Hiscox, S; James, M; Jordan, NJ; Morgan, L; Nicholson, RI; Smith, C; Taylor, KM | 1 |
| Bai, L; Chang, YM; Evans, CP; Kung, HJ; Liu, S; Yang, JC | 1 |
| Cao, PJ; Dhani, N; Do, T; Hedley, DW; Hill, RP; Magalhaes, JM; Pham, NA; Schwock, J | 1 |
| Ashton, GH; Baldeschi, C; Brunton, VG; Canel, M; Doyle, B; Frame, MC; Green, TP; Mackintosh, LJ; Mason, SM; Sansom, OJ; Serrels, A; Serrels, B | 1 |
| Borowsky, AD; Busby, JE; Evans, CP; Kung, HJ; Ok, JH; Yang, JC | 1 |
| Saad, F | 1 |
| Bacic, B; Gwanmesia, PM; Ottmann, OG; Romanski, A; Ruthardt, M; Schwarz, K | 1 |
| Andersen, P; Poulsen, HS; Stockhausen, MT; Villingshøj, M | 1 |
| Evans, CP; Gandara, DR; Gautschi, O; Green, TP; Gumerlock, PH; Kung, HJ; Lara, PN; Mack, PC; Purnell, PR; Tepper, CG | 1 |
| French, JD; Grzywa, RL; Haugen, BR; Kerege, AA; Schweppe, RE; Sharma, V | 1 |
| de Vries, TJ; Everts, V; Green, TP; James, N; Klein-Nulend, J; Mullender, MG; Semeins, CM; van Duin, MA | 1 |
| Allen, J; Bermingham, A; Boyer, B; Carragher, N; Costello, GF; Curwen, J; Davies, BR; Elvin, P; Fennell, M; Green, TP; Hargreaves, J; Hennequin, LF; Hickinson, DM; Holdgate, GA; Jacobs, V; Logie, A; Plé, PA; Ward, WH; Whittaker, R; Wilkinson, RW | 1 |
| Chatta, G; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Posadas, E; Quinn, DI; Stadler, W; Twardowski, P | 1 |
| Chen, Y; Gonzalez-Angulo, A; Guggisberg, N; Hennessy, B; Jorda, M; Mills, GB; Slingerland, JM; Tan, CK | 1 |
| De Oliveira, E; Green, TP; Hidalgo, M; Jimeno, A; Messersmith, WA; Morgan, S; Rajeshkumar, NV; Tan, AC; Walker, J; Warren, MV; Womack, C; Wombwell, H | 1 |
| Anderson, KC; Azab, AK; Azab, F; Farag, M; Ghobrial, IM; Jia, X; Leleu, X; Melhem, MM; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A | 1 |
| Clack, G; Eastell, R; Finkelman, RD; Hannon, RA; Lockton, JA; Rimmer, M; Swaisland, A | 1 |
| Bai, L; Evans, CP; Gao, AC; Kung, HJ; Yang, JC; Yap, S | 1 |
| Bönisch, H; Bryce, RA; Dive, C; Ghattas, M; Green, TP; Hickinson, DM; Morrow, CJ; Smith, C | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 2 |
| Alvarez, EA; Azzam, D; Chen, Y; Guggisberg, N; Hennessy, BT; Jordà, M; Ju, Z; Slingerland, JM; Wander, SA | 1 |
| Arcaroli, JJ; Eckhardt, SG; Elvin, P; Gao, D; Messersmith, WA; Powell, RW; Tan, AC; Touban, BM; Varella-Garcia, M | 1 |
| Chetty, R; Dalton, RN; Iacona, RB; Stuart, M; Swaisland, A | 1 |
| Baselga, J; Casado, E; Cervantes, A; Chirivella, I; Elvin, P; Hamberg, P; Hoekman, K; Hurwitz, HI; Iacona, R; Jodrell, DI; Martinelli, E; Swaisland, A; Tabernero, J | 1 |
| Dempke, W; Zippel, R | 1 |
| Dong, M; Lepler, S; Pampo, C; Rice, L; Siemann, DW | 1 |
| Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W | 1 |
| Baxi, S; Carlson, D; Fury, MG; Haque, S; Kelly, KW; Lipson, BL; Pfister, DG; Shen, R; Stambuk, H | 1 |
| Alcindor, T; Au, HJ; Jarvi, A; MacAlpine, K; Mackay, HJ; McWhirter, E; Oza, AM; Wang, L; Wright, JJ | 1 |
| Hofbauer, LC; Khosla, S; Rachner, TD | 1 |
| Eadens, M; Messersmith, W; Puls, LN | 1 |
| Bareford, MD; Cruickshanks, N; Dai, Y; Dent, P; Grant, S; Hamed, HA; Hubbard, N; Mitchell, C; Tang, Y; Tye, G; Yacoub, A | 1 |
| Abbruzzi, A; Bromberg, J; Caravelli, J; Dang, C; Gucalp, A; Hudis, C; Massague, J; Norton, L; Patil, S; Pellegrino, C; Santamauro, J; Sparano, JA; Theodoulou, M; Traina, TA | 1 |
| Bai, L; Evans, CP; Kung, HJ; Mack, PC; Ok, JH; Yang, JC | 1 |
| Chambers, AF; Mutrie, JC; Tuck, AB | 1 |
| Botti, G; D'Antonio, A; De Luca, A; Hendrix, MJ; Hsu, MY; Lamura, L; Margaryan, N; Mari, E; Normanno, N; Pirozzi, G; Roma, C; Salomon, DS; Strizzi, L | 1 |
| Egan, C; Koro, K; Magliocco, A; Parkin, S; Pohorelic, B; Singh, R; Yang, AD | 1 |
| Brown, KH; Drevs, J; Eberhardt, WE; Gauler, TC; Le Scouiller, S; Marotti, M; Schneider, V; Schultheis, B; Strumberg, D; Trarbach, T | 1 |
| Chen, L; Gu, J; Liu, H; Sun, L; Wang, S; Wen, Y; Xu, J; Yun, X; Zhou, L | 1 |
| Kameda, Y; Koizume, S; Matsukuma, S; Miyagi, Y; Nakamura, Y; Nakayama, H; Sakuma, Y; Yamazaki, Y; Yokose, T; Yoshihara, M | 1 |
| Baselga, J; Clack, G; Eastell, R; Finkelman, RD; Gossiel, F; Hannon, RA; Iacona, RB; Rimmer, M | 1 |
| Arozarena, I; Ehrhardt, M; Ferguson, J; Wellbrock, C | 1 |
| Briscoe, DM; Bruneau, S; Datta, D; Flaxenburg, JA; Pal, S | 1 |
| Ye, P | 1 |
| Boku, N; Fujisaka, Y; Goto, I; Kurata, T; Machida, N; Onozawa, Y; Shi, X; Shimada, H; Watanabe, J; Yamazaki, K; Yasui, H | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Farsaci, B; Greiner, JW; Sabzevari, H; Schlom, J; Takai, S | 1 |
| Aglietta, M; Cavalloni, G; Gammaitoni, L; Leone, F; Marchiò, S; Migliardi, G; Peraldo-Neia, C; Sarotto, I; Soster, M | 1 |
| Chen, CY; Tou, WI | 2 |
| Dong, M; Pampo, C; Shi, W; Siemann, DW | 1 |
| Aamdal, S; Barrett, S; Barriuso, J; Boven, E; Burke, W; de Vries, EG; Emeribe, U; Freyer, G; Hartog, V; Jones, R; Kaye, S; Kristensen, GB; Kuenen, B; Nyakas, M; Pietersma, D; Pujade-Lauraine, E; Ruijter, R; Sandhu, S; Stuart, M; Tan, DS | 1 |
| Arcaroli, JJ; Bemis, L; Dasari, A; Eckhardt, SG; Messersmith, WA; Pitts, TM; Powell, RW; Quackenbush, KS; Reinemann, JM; Spreafico, A; Tan, AC; Touban, BM; Varella-Garcia, M | 1 |
| Boult, JK; Elvin, P; Gilmour, LD; Halliday, J; Jacobs, V; Jamin, Y; Robinson, SP; Ryan, AJ; Walker-Samuel, S; Waterton, JC | 1 |
| Ambudkar, SV; Chen, XG; Chen, ZS; Fu, LW; He, JH; Liang, YJ; Liu, KJ; Sim, HM; Singh, S; Sodani, K; Su, XD; Talele, TT; Wang, F; Wu, HY; Xie, JD | 1 |
| Azzam, D; da Silva, T; Gilbert, CA; Hevia-Paez, P; Ince, TA; Levin, ER; Lu, Y; Mills, GB; Pedram, A; Rabinovich, B; Reis, IM; Simpkins, F; Slingerland, JM; Sun, J; Ullmer, W; Verhaak, RG; Xu, XX; Yang, JY | 1 |
| Bang, YJ; Elvin, P; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, A; Nam, HJ; Oh, DY; Song, SH; Yoon, YK | 1 |
| Clark, JI; Gajewski, TF; Gangadhar, TC; Karrison, T | 1 |
| Mimoso Pinhanços, S; Pieters, R; Schneider, P; Spijkers-Hagelstein, JA; Stam, RW | 1 |
| Arcaroli, J; Dasari, A; Erlichman, C; Foster, NR; Hidalgo, M; McManus, M; Messersmith, WA; Nallapareddy, S; Picus, J; Powell, R; Quackenbush, K; Tan, AC; Wright, J | 1 |
| de Wispelaere, M; LaCroix, AJ; Yang, PL | 1 |
| Wadman, M | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Lewis, TC; Prywes, R | 1 |
| Chae, IG; Chun, KS; Kwon, TK; Min, KJ; Woo, SM | 1 |
| Dai, B; Fang, B; Gao, W; Hofstetter, WL; Lu, H; Meng, J; Minna, J; Roth, JA; Swisher, SG; Wang, L; Wu, S | 1 |
| Barth, C; Massard, C; Vignot, S | 1 |
| Goss, GD; Hirsh, V; Laurie, SA; Leighl, NB; Nicholas, G; Oza, A; Philip, L; Reaume, MN; Schwock, J; Shepherd, FA; Tsao, MS; Wang, L; Wright, JJ | 1 |
| Chai, C; Choolani, M; Chu, YS; Chung, VY; Huang, RY; Kuay, KT; Lai, HC; Lee, YF; Low, JJ; Matsumura, N; Mori, S; Ng, AH; Pietschmann, E; Sim, WJ; Tan, TZ; Thiery, JP; Wong, MK | 1 |
| El Touny, LH; Green, JE; Hoenerhoff, MJ; Khanna, C; Mendoza, A; Vieira, A | 1 |
| Beyer, EC; Dudley, SC; Efimov, IR; Gemel, J; Greener, ID; Liu, H; Ng, FS; Rutledge, CA; Sergeyenko, AM; Sovari, AA; Sulkin, MS | 1 |
| Erdmann, F; Platzer, C; Rohe, A; Schmidt, M; Sippl, W; Slynko, I; Wichapong, K | 1 |
| Fukami, K; Ito, Y; Kamata, R; Sakai, R; Takanashi, M; Yamaguchi, H; Yanagihara, K; Yoshida, N | 1 |
| Cho, H; Gray, NS; Liu, S; Vetter, ML; Wang, J; Yang, PL; Zhang, J; Zhang, W; Zhang, Z | 1 |
| Bianco, R; D'Amato, C; D'Amato, V; Damiano, V; De Placido, S; Formisano, L; Iommelli, F; Marciano, R; Nappi, L; Parsons, SJ; Raimondo, L; Rosa, R; Scorziello, A; Troncone, G; Veneziani, B | 1 |
| Adjei, AA; Foster, NR; Grainger, AV; Marks, R; Molina, JR; Nelson, GD; Reungwetwattana, T; Steen, PD; Stella, PJ; Wright, J | 1 |
| Fu, J; Gou, W; Han, X; Li, L; Li, X; Yang, T; Zhang, Y | 1 |
| Antony, V; Cai, GQ; Che, P; Desai, LP; Ding, Q; Han, X; Hu, M; Liu, G; Liu, RM; Luckhardt, T; O'Reilly, PJ; Siegal, GP; Thannickal, VJ; Zhou, Y | 1 |
| Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L | 1 |
| Liu, Y; Wang, Y; Wu, W; Xu, Y; Zhang, H | 1 |
| Ablack, A; Carmine-Simmen, K; Chambers, AF; Chien, AE; Chin, CA; Courtneidge, SA; Hague, MN; Leith, SJ; Leong, HS; Lewis, JD; McPherson, VA; Postenka, CO; Robertson, AE; Stoletov, K; Turley, EA | 1 |
| Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS | 1 |
| Gunther, EC; Haas, LT; Jeng, AT; Kaufman, AC; Kostylev, MA; Nygaard, HB; Robinson, SA; Salazar, SV; Strittmatter, SM; van Dyck, CH; Yang, J | 1 |
| Cui, A; Hua, H; Jiang, Y; Kong, Q; Luo, T; Shao, T; Song, P | 1 |
| Althouse, SK; Burns, M; Gubens, MA; Loehrer, PJ; Pedro-Salcedo, MS; Perkins, SM; Wakelee, HA | 1 |
| Abbruzzese, JL; Eng, C; Fogelman, D; Gallick, G; Jacobs, C; Jimenez, CA; Kopetz, S; Malik, Z; Morris, J; Overman, MJ; Parikh, N; Qiao, W; Reddy, SM; Shureiqi, I; Wolff, RA | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Chua, KN; Goh, BC; Huynh, H; Kong, LR; Ng, HC; Ong, WR; Sim, WJ; Thiery, JP | 1 |
| Ambrose, A; Arun, BK; Brady, SW; Chang, CC; Dobbs, J; Ibarra-Drendall, C; Jain, S; Jia, W; Kyrish, M; Li, P; Richards-Kortum, R; Seewaldt, VL; Sistrunk, C; Tkaczyk, TS; Wang, H; Wang, X; Yu, D; Zhang, Q; Zhao, H | 1 |
| Ahmed, RS; Gururajan, M; Karrison, T; O'Donnell, PH; Posadas, EM; Shen, J; Sievert, M; Stadler, WM; Szmulewitz, RZ; Wade, JL | 1 |
| Ackerman, C; Beltran, L; Bhal, A; Boleti, E; Brown, J; Chowdhury, S; Crabb, S; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Webb, A | 1 |
| Abad, S; Auladell, C; Beas-Zarate, C; Camins, A; Ettcheto, M; Folch, J; García, ML; Olloquequi, J; Petrov, D; Sánchez-López, E | 1 |
| Andrew, D; De Felice, M; Escott, KJ; Holen, I; Lambert, D | 1 |
| Baron, F; Beguin, Y; Binsfeld, M; Caers, J; Carmeliet, G; Cohen-Solal, M; Dubois, S; Heusschen, R; Léonard, A; Mahli, N; Marty, C; Menu, E; Moermans, K; Muller, J; Plougonven, E | 1 |
| Batliner, J; Fey, MF; Gautschi, O; Gugger, M; Rothschild, SI; Tschan, MP | 1 |
| Huang, XX; Mao, SS; Wu, JS; Xiong, J; Yu, XN | 1 |
| Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Elexpuru Zabaleta, M; Galeazzi, R; Gambini, V; Garulli, C; Hysi, A; Iezzi, M; Kalogris, C; Marchini, C; Orlando, F; Pietrella, L; Provinciali, M; Tilio, M; Wang, J | 1 |
| Dong, J; Li, B; Lu, C; Meng, Y; Wang, C; Wang, H; Wang, L; Yang, Y; Yu, X; Zhang, Y; Zhao, J; Zhao, Y | 1 |
| Coldren, CD; Geraci, MW; Heasley, LE; Helfrich, BA; Mickler, EA; Nakachi, I; Olson, CJ; Rice, JL; Spillman, MA; Stearman, RS | 1 |
| Chen, J; Peng, Y; Zheng, J | 1 |
| Hu, XC; Lin, C; Liu, MM; Tao, ZH; Wu, ZH; Zhang, J | 1 |
| Behnam, B; Gardaneh, M; Kaviani, A; Shojaei, S | 1 |
| Alesi, GN; Chen, ZG; Chun, J; Fan, J; Jin, L; Kang, S; Kang, Y; Khuri, FR; Li, D; Magliocca, KR; Pan, C; Shin, DM | 1 |
| Bertrand, J; Ciarimboli, G; Edemir, B; Harrach, S; Pap, T; Schmidt-Lauber, C | 1 |
| Chang, F; Flavahan, NA; Flavahan, S | 1 |
| Nygaard, HB | 1 |
| Bracho, O; Burns, SS; Chang, LS; Copik, AJ; Dinh, CT; Fernandez-Valle, C; Franco, MC; Fuse, MA; Liu, XZ; Mittal, R; Plati, SK; Shen, R; Soulakova, JN; Telischi, FF; Yan, D | 1 |
| Kibaly, C; Law, PY; Liu, JG; Loh, HH; McGarrah, PW; Song, KY; Wang, YJ; Xu, C; Zhang, L | 1 |
| Avale, ME; Bernardi, MA; Bordone, MP; Damianich, A; Ferrario, JE; Gershanik, OS; Gomez, G; Hanger, DP; Isaja, L; Sanz-Blasco, S; Taravini, IR | 1 |
| Gray, J; Jokela, T; LaBarge, MA; Lin, CH | 1 |
| Katsuta, E; Rashid, OM; Takabe, K | 1 |
| Smith, LM; Strittmatter, SM; Zhu, R | 1 |
| Accogli, T; Ballerini, P; Bastie, JN; Buffière, A; Delva, L; Lucchi, G; Pflumio, F; Quéré, R; Saint-Paul, L; Uzan, B | 1 |
| Chen, W; Guan, X; Jin, J; Sun, Z; Tang, L; Yang, F | 1 |
| Bai, X; Cai, D; Huang, B; Jiang, W; Jiang, Y; Li, K; Li, M; Liu, A; Shen, J; Song, Q; Xu, S; Zhang, Y | 1 |
| Fang, H; Guan, X; Huang, D; Jin, J; Yang, F | 1 |
| Alrabiah, H; Attwa, MW; Darwish, HW; Kadi, AA | 1 |
| Berger, A; Ron, D | 1 |
| Baric, RS; Go, YY; Jung, E; Kim, M; Shin, JS | 1 |
| Chemmalakuzhy, R; Lang, L; Shay, C; Teng, Y; Thakkar, P; Wang, X; Xiong, Y | 1 |
| Cai, G; Chen, J; Chu, L; Dai, W; Ding, P; Gu, H; Hu, W; Li, L; Lv, X; Wang, Q; Zhang, L; Zhang, P; Zhang, W; Zhang, X; Zhao, K; Zhou, D; Zhou, Y | 1 |
| Lin, M; Yao, Z; Zhang, C; Zhao, N | 1 |
| Hino, K; Horigome, K; Ikeya, M; Komura, S; Nagata, S; Nishio, M; Ohta, A; Okanishi, Y; Toguchida, J; Yamada, Y; Zhao, C | 1 |
| Berger, AL; Cross, A; Morisot, N; Phamluong, K; Ron, D | 1 |
| Brown, KK; Chan, H; Chheang, C; Daly, RJ; Huang, C; Lee, RS; Li, F; Ma, X; Mitchell, CA; Nguyen, E; Rodgers, SJ; Schittenhelm, RB; Simpson, KJ; Song, J; Wu, J; Zhang, L | 1 |
| Ackerman, C; Bahl, A; Beltran, L; Boleti, E; Brown, J; Chowdhury, S; Crabb, SJ; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Shepherd, STC; Webb, A; Wimalasingham, A | 1 |
| Bian, X; Guo, Z; Kong, L; Mu, L; Wu, L; Wu, S; Yan, F; Ye, J; Yin, X | 1 |
| Bobera, J; Dupuy, AJ; Feddersen, CR; Jennings, BM; Mullen, SA; Riordan, JD; Schillo, JL; Stipp, CS; Varzavand, A; Vaughn, HR; Voigt, AP; Wadsworth, LS; Zhu, EY | 1 |
| Chen, S; Li, D; Li, J; Liu, Q; Wang, L; Zhao, J | 1 |
| Dabo, AJ; Ezegbunam, W; Foronjy, RF; Geraghty, P; Lora, A; Majka, SM; Moon, J; Railwah, C; Wyman, AE | 1 |
| Lang, L; Shay, C; Teng, Y; Wang, X; Xiong, Y; Zhao, X | 1 |
| Barnes, KR; Claus, LN; Cozzi, RRF; Fougere, B; Francis, ME; Marshall, WS | 1 |
| Bu, Y; Chang, F; Jia, F; Jia, Q; Liao, X; Ren, X; Song, G; Xiao, X; Xu, Z; Zhang, M | 1 |
| Hwang, JS; Jang, BK; Kang, YN; Kim, MK; Lee, JH; Lee, SH; Park, KG; Seo, HY | 1 |
| Kabir, MZ; Magesvaran, MKA; Mohamad, SB; Ridzwan, NFW; Tayyab, S | 1 |
| Chiasseu, M; Chyung, A; Fesharaki-Zadeh, A; Luo, A; Nies, SH; Smith, LM; Strittmatter, SM; Takahashi, H; Tang, SJ | 1 |
| Inoue, S; Koyama, Y; Naka, N; Nakagaki, T; Ogura, S; Oka, N; Terashi, M; Yamaki, K | 1 |
| Chen, CJ; Chiu, LY; Hsin, IL; Ko, JL; Ou, CC; Sheu, GT; Tsai, JN; Wu, WJ | 1 |
| Deng, Z; Du, Z; Li, X; Tao, Z; Wang, H; Zhou, Y | 1 |
| Kumar, R; Pavlov, PF; Wang, L; Winblad, B | 1 |
| Dimas, K; Komini, C; Lambrianidou, A; Sereti, E; Soupsana, K; Trangas, T | 1 |
| Fischer, K; Haupt, J; Hildebrand, L; Hildebrandt, S; Kampfrath, B; Knaus, P; Stachelscheid, H | 1 |
| Fu, J; Li, ZY; Lu, J; Luo, XM; Wu, WY; Zhang, M; Zhao, J | 1 |
| Chen, L; Chen, Q; Guo, X; Huang, L; Jiang, C; Liu, X; Shu, X; Wang, H; Wang, X; Wang, Z; Wei, T; Wu, Q; Xiao, J; Yang, B; Zhang, X; Zhang, Y; Zheng, S | 1 |
| Bagarova, J; Bocobo, GA; Bullock, AN; Dey, D; Economides, AN; Huang, X; Kerr, G; Lee, A; Mohedas, AH; Place, ES; Sanderson, PE; Shen, Y; Smith, JC; Williams, E; Xia, DD; Yu, PB; Zheng, W | 1 |
| Carlson, S; Gregory-Flores, A; Hinojo-Perez, A; Olson, A; Sharma, S; Thippeswamy, T | 1 |
| Camphausen, K; Kil, WJ; Kramp, TR; Lee, J; Tofilon, PJ; Yun, HS | 1 |
| Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y | 1 |
| DeMartini, K; Dunlap, A; Gallagher, A; Krystal, JH; O'Malley, SS; Patel, KT; Pearlson, GD; Potenza, MN; Stevens, MC | 1 |
| An, X; Jia, ZW; Su, YX; Wang, XJ; Yu, JP; Zhang, J | 1 |
| Anderman, MF; Bhargava, D; Boccuzzi, L; de Miguel, FJ; Doroshow, JH; Durkin, ME; Lowy, DR; Papageorge, AG; Politi, K; Qian, X; Tripathi, BK; Walters, KJ; Wang, D | 1 |
| Bullock, AN; Eekhoff, EMW; Keen, R; Smilde, BJ; Stockklausner, C; van Schoor, NM; von Delft, A; Whittaker, A; Yu, PB | 1 |
| Lang, L; Teng, Y | 1 |
| Richeldi, L; Sgalla, G | 1 |
14 review(s) available for quinazolines and saracatinib
| Article | Year |
|---|---|
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Topics: Benzodioxoles; Clinical Trials, Phase I as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Thiazoles | 2006 |
Src as a therapeutic target in men with prostate cancer and bone metastases.
Topics: Antineoplastic Agents; Benzodioxoles; Bone Neoplasms; Dasatinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Receptors, Androgen; src-Family Kinases; Thiazoles | 2009 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
[SRC kinases in tumor therapy].
Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2010 |
Osteoporosis: now and the future.
Topics: Absorptiometry, Photon; Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodioxoles; Biphenyl Compounds; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Remodeling; Bone Resorption; Calcium; Denosumab; Diphosphonates; Female; Genetic Markers; Humans; Intercellular Signaling Peptides and Proteins; Middle Aged; Osteoblasts; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quinazolines; Randomized Controlled Trials as Topic; RANK Ligand; Risk Assessment; Risk Factors; Vitamin D Deficiency; Wnt Proteins | 2011 |
Current status of SRC inhibitors in solid tumor malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2011 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
[Bone targeted therapies: new agents].
Topics: Aniline Compounds; Benzodioxoles; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Dasatinib; Diphosphonates; Humans; Molecular Targeted Therapy; Nitriles; Parathyroid Hormone-Related Protein; Pyrimidines; Quinazolines; Quinolines; RANK Ligand; Receptors, Chemokine; src-Family Kinases; Thiazoles; Transforming Growth Factor beta1 | 2013 |
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzamides; Benzodioxoles; Brain; Disease Models, Animal; Humans; Mice; Neurons; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Quinazolines; Receptor, Metabotropic Glutamate 5; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Synapses; Thiazoles | 2016 |
Targeting Fyn Kinase in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzodioxoles; Enzyme Inhibitors; Humans; Prion Proteins; Proto-Oncogene Proteins c-fyn; Quinazolines | 2018 |
Targeting the intracellular signaling "STOP" and "GO" pathways for the treatment of alcohol use disorders.
Topics: Alcohol Drinking; Alcoholism; Animals; Benzodioxoles; Brain-Derived Neurotrophic Factor; Drug Delivery Systems; Ethanol; Humans; Intracellular Fluid; Quinazolines; Signal Transduction; Sirolimus; Treatment Outcome | 2018 |
Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
Topics: Alzheimer Disease; Animals; Benzodioxoles; Cholinesterase Inhibitors; Cholinesterases; Curcumin; Humans; Molecular Targeted Therapy; Neurofibrillary Tangles; Neuroprotective Agents; Phosphorylation; Plaque, Amyloid; Protein Aggregation, Pathological; Protein Processing, Post-Translational; Quinazolines; Receptors, N-Methyl-D-Aspartate; tau Proteins; Thiadiazoles | 2021 |
24 trial(s) available for quinazolines and saracatinib
| Article | Year |
|---|---|
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzodioxoles; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Humans; Lymphopenia; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.
Topics: Adult; Benzodioxoles; Biomarkers; Bone Remodeling; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Men's Health; Quinazolines | 2010 |
Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.
Topics: Adolescent; Adult; Benzodioxoles; Creatinine; Double-Blind Method; Humans; Kidney; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Young Adult | 2010 |
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Young Adult | 2010 |
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden | 2012 |
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Benzodioxoles; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Young Adult | 2011 |
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Benzodioxoles; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Stomach Neoplasms | 2012 |
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; New York City; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2011 |
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2012 |
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Topics: Adult; Aged; Benzodioxoles; Biomarkers, Tumor; Bone Remodeling; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Young Adult | 2012 |
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Topics: Adult; Aged; Asian People; Benzodioxoles; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2013 |
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2012 |
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; T-Lymphocytes; Treatment Outcome | 2013 |
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Topics: 3' Untranslated Regions; Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Quinazolines; Receptors, Cell Surface; src-Family Kinases | 2012 |
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Survival Rate | 2014 |
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Small Cell Lung Carcinoma; src-Family Kinases; Treatment Outcome | 2014 |
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms | 2014 |
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Carcinoma; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Humans; Male; Middle Aged; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; src-Family Kinases; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Failure; Young Adult | 2015 |
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Benzodioxoles; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2015 |
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Chicago; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinazolines | 2016 |
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).
Topics: Aged; Benzodioxoles; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Quinazolines; Vascular Endothelial Growth Factor A | 2016 |
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Kidney Neoplasms; Male; Prognosis; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial.
Topics: Alcohol Drinking; Alcoholism; Benzodioxoles; Humans; Magnetic Resonance Imaging; Motivation; Pilot Projects; Quinazolines; Reward | 2022 |
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).
Topics: Adolescent; Adult; Aged; Benzodioxoles; Double-Blind Method; Humans; Middle Aged; Multicenter Studies as Topic; Mutation; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Randomized Controlled Trials as Topic; Young Adult | 2022 |
122 other study(ies) available for quinazolines and saracatinib
| Article | Year |
|---|---|
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzodioxoles; Cell Proliferation; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Dogs; Enzyme Inhibitors; Female; Humans; Indicators and Reagents; Male; Mice; Mice, Nude; Models, Molecular; Neoplasm Invasiveness; Protein-Tyrosine Kinases; Quinazolines; Rats; Solubility; src-Family Kinases; Structure-Activity Relationship; Thermodynamics; Transplantation, Heterologous | 2006 |
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Dose-Response Relationship, Drug; Drug Synergism; Estrogen Receptor alpha; Estrogens; Humans; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; src-Family Kinases; Tamoxifen | 2006 |
Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Topics: Animals; Benzodioxoles; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Feasibility Studies; Female; Focal Adhesion Kinase 1; Humans; Immunoenzyme Techniques; Lung Neoplasms; Paxillin; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Nude; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Focal Adhesion Protein-Tyrosine Kinases; Humans; Neoplasm Invasiveness; Phosphorylation; Quinazolines; src-Family Kinases; Treatment Outcome | 2009 |
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Topics: Antineoplastic Agents; Benzodioxoles; beta Catenin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crk-Associated Substrate Protein; Cyclin D; Cyclins; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Molecular Structure; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Repressor Proteins; src-Family Kinases; Time Factors | 2008 |
Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.
Topics: Animals; Benzodioxoles; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hypoxia; Male; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor | 2009 |
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Humans; Keratinocytes; Keratosis; Male; Mice; Middle Aged; Papilloma; Precancerous Conditions; Quinazolines; Skin Neoplasms; src-Family Kinases; Tetradecanoylphorbol Acetate | 2009 |
Research provides new hope for tamoxifen-resistant breast cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzodioxoles; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Quinazolines; Tamoxifen; United Kingdom | 2008 |
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Benzodioxoles; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Enzyme Activation; Focal Adhesion Kinase 1; Gastrin-Releasing Peptide; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; src-Family Kinases; Transfection; Xenograft Model Antitumor Assays | 2009 |
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzodioxoles; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; src-Family Kinases | 2009 |
Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Survival; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Chromones; Focal Adhesion Protein-Tyrosine Kinases; Humans; Janus Kinase 3; Lung Neoplasms; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor | 2009 |
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma; Carcinoma, Papillary; Cell Culture Techniques; Cell Proliferation; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Thyroid Neoplasms; Tumor Cells, Cultured | 2009 |
The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
Topics: Actins; Animals; Benzodioxoles; Blotting, Western; Bone and Bones; Bone Resorption; Cell Adhesion; Cell Differentiation; Cell Movement; Cells, Cultured; Coculture Techniques; Female; Fetus; Humans; Leukocytes, Mononuclear; Mice; Organ Culture Techniques; Osteoclasts; Phosphorylation; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skull | 2009 |
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clinical Trials, Phase II as Topic; Focal Adhesion Kinase 1; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; NIH 3T3 Cells; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; src-Family Kinases; Transplantation, Heterologous; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodioxoles; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphatidylinositol 3-Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Biomarkers, Tumor; Female; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Paxillin; Proto-Oncogene Proteins pp60(c-src); Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2009 |
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Topics: Benzodioxoles; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Chemotaxis; Cytotoxins; Drug Evaluation, Preclinical; Humans; Oncogene Protein pp60(v-src); Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Waldenstrom Macroglobulinemia | 2009 |
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Bone and Bones; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Male; Mice; Neoplasm Invasiveness; Osteoclasts; Osteogenesis; Osteolysis; Protein Kinase Inhibitors; Quinazolines; Radiography; RANK Ligand; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2010 |
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cisplatin; Colorectal Neoplasms; DNA Damage; DNA, Neoplasm; Drug Administration Schedule; Drug Interactions; Fluorouracil; HCT116 Cells; Humans; Models, Molecular; Organic Cation Transport Proteins; Organic Cation Transporter 2; Organoplatinum Compounds; Oxaliplatin; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Transfection | 2010 |
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; G1 Phase; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Quinazolines; src-Family Kinases; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Separation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Topics: Animals; Apoptosis; Benzodioxoles; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Disease Models, Animal; Female; Fibrosarcoma; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Lung Neoplasms; Mice; Mice, Inbred C3H; Phosphorylation; Quinazolines; Sarcoma, Experimental; src-Family Kinases; Survival Rate; Tumor Cells, Cultured | 2010 |
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Death; Cell Line, Transformed; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dasatinib; Female; Fibroblasts; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Protease Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; Quinazolines; Radiation Tolerance; src-Family Kinases; Thiazoles | 2011 |
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Topics: Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Gene Knockdown Techniques; HSP90 Heat-Shock Proteins; Humans; Models, Biological; Neoplastic Stem Cells; Osteopontin; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transfection | 2011 |
Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Topics: Activin Receptors, Type I; Benzamides; Benzodioxoles; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dioxoles; Flow Cytometry; GPI-Linked Proteins; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Smad Proteins; src-Family Kinases; Tumor Cells, Cultured | 2011 |
Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Topics: Benzodioxoles; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Coculture Techniques; Culture Media, Conditioned; Enzyme Activation; Female; Gene Expression Profiling; Humans; Male; Mesenchymal Stem Cells; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; src-Family Kinases; Tumor Microenvironment | 2012 |
Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.
Topics: Aged; Aged, 80 and over; Animals; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Chlorocebus aethiops; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins pp60(c-src); Quinazolines; RNA Interference; Signal Transduction; Vero Cells; Xenograft Model Antitumor Assays | 2011 |
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Topics: Acrylamides; Adenocarcinoma; Aged; Aged, 80 and over; Aniline Compounds; Anoikis; Benzodioxoles; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; src-Family Kinases; Sulfonamides | 2012 |
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Topics: Benzimidazoles; Benzodioxoles; Cell Adhesion; Cell Division; Collagen; Humans; Integrin beta1; MAP Kinase Kinase Kinases; Melanoma; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2013 |
TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor.
Topics: Benzodioxoles; Cell Movement; Cell Proliferation; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Luciferases; Neovascularization, Physiologic; Promoter Regions, Genetic; Quinazolines; RNA, Small Interfering; src-Family Kinases; TNF Receptor-Associated Factor 6; Transcriptional Activation; Vascular Endothelial Growth Factor A | 2012 |
Modulation of epithelial tight junctions by TGF-beta 3 in cultured oral epithelial cells.
Topics: Benzodioxoles; Cell Adhesion Molecules; Cell Line, Tumor; Cell Membrane Permeability; Claudins; CSK Tyrosine-Protein Kinase; Epithelial Cells; Gene Expression Profiling; Gingiva; Humans; Membrane Proteins; Occludin; Periodontal Pocket; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recombinant Proteins; src-Family Kinases; Tight Junctions; Transforming Growth Factor beta3 | 2012 |
Distinct effects of saracatinib on memory CD8+ T cell differentiation.
Topics: Animals; Antigens, Viral; Benzodioxoles; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Humans; Hyaluronan Receptors; Immunologic Memory; Influenza A virus; Influenza Vaccines; Interferon-gamma; L-Selectin; Mice; Mice, Transgenic; Neoplasms, Experimental; Quinazolines; src-Family Kinases; Viral Proteins | 2012 |
Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Topics: Aged; Animals; Antineoplastic Agents; Benzodioxoles; Biliary Tract Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phosphorylation; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Topics: Benzodioxoles; Benzofurans; Binding Sites; Catalytic Domain; Coumarins; Dipeptides; Glucosides; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Ligands; Medicine, Chinese Traditional; Molecular Dynamics Simulation; Quantitative Structure-Activity Relationship; Quinazolines; src-Family Kinases; Thermodynamics | 2012 |
Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Topics: Animals; Benzodioxoles; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases | 2012 |
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Topics: 3' Untranslated Regions; Animals; Benzodioxoles; Biomarkers, Tumor; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Profiling; Humans; Immunoblotting; Immunoprecipitation; Mice; MicroRNAs; Mutation; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2012 |
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.
Topics: Animals; Benzodioxoles; Biomarkers, Tumor; Blood Vessels; Cell Hypoxia; Cell Line, Tumor; False Negative Reactions; Female; Humans; Magnetic Resonance Imaging; Male; Mammary Neoplasms, Experimental; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rats; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodioxoles; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; HEK293 Cells; HeLa Cells; HL-60 Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rho-Associated Kinases | 2013 |
Traditional Chinese medicine as dual guardians against hypertension and cancer?
Topics: Antihypertensive Agents; Antineoplastic Agents; Benzodioxoles; Databases, Factual; Ligands; Medicine, Chinese Traditional; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Quinazolines; src-Family Kinases | 2012 |
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Ovarian Neoplasms; Protein Binding; Protein Transport; Quinazolines; Receptors, Estrogen; src-Family Kinases; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Female; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Expression; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Annexin A2; Benzodioxoles; Cell Proliferation; Drug Resistance, Neoplasm; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Myeloid-Lymphoid Leukemia Protein; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Quinazolines; RNA, Messenger; S100 Proteins; src-Family Kinases | 2013 |
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Topics: Antibodies, Monoclonal; Benzodioxoles; Blotting, Northern; Blotting, Western; Cell Survival; Dasatinib; Dengue Virus; Dimethyl Sulfoxide; DNA Primers; HEK293 Cells; Humans; Mycophenolic Acid; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Quinazolines; Replicon; RNA Interference; RNA, Viral; Thiazoles; Virus Replication | 2013 |
NIH gambles on recycled drugs.
Topics: Alzheimer Disease; Benzodioxoles; Drug Repositioning; Enzyme Inhibitors; Financing, Government; Humans; National Institutes of Health (U.S.); Quinazolines; United States | 2013 |
Serum regulation of Id1 expression by a BMP pathway and BMP responsive element.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Blotting, Western; Bone Morphogenetic Protein Receptors; Bone Morphogenetic Proteins; Cells, Cultured; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Luciferases; Mice; NIH 3T3 Cells; Promoter Regions, Genetic; Quinazolines; Real-Time Polymerase Chain Reaction; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Serum; Signal Transduction; Smad Proteins; src-Family Kinases | 2013 |
Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Topics: Alprostadil; Antioxidants; Benzodioxoles; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Dinoprostone; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; GTP-Binding Proteins; HCT116 Cells; HT29 Cells; Humans; Integrases; Kidney Neoplasms; Phosphorylation; Prostaglandin Antagonists; Quinazolines; Receptors, Prostaglandin E, EP2 Subtype; RNA Interference; RNA, Small Interfering; Signal Transduction; Silymarin; src-Family Kinases; STAT3 Transcription Factor; Wound Healing; Xanthones | 2015 |
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor Binding Protein 2; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).
Topics: Animals; Anoikis; Antineoplastic Agents; Benzodioxoles; Cadherins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Female; Fluorescent Antibody Technique; Humans; Mice; Ovarian Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays | 2014 |
c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Benzodioxoles; Connexin 43; CSK Tyrosine-Protein Kinase; Death, Sudden; Echocardiography; Enzyme Inhibitors; Gap Junctions; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Protein Phosphatase 1; Quinazolines; Reactive Oxygen Species; src-Family Kinases | 2014 |
Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors.
Topics: Aza Compounds; Benzodioxoles; Drug Design; Humans; Ligands; Membrane Proteins; Molecular Docking Simulation; Morpholines; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridones; Pyrimidines; Quinazolines | 2014 |
Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Peritoneum; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; src-Family Kinases; Stomach Neoplasms | 2014 |
Fluorescent visualization of Src by using dasatinib-BODIPY.
Topics: Animals; Benzodioxoles; Boron Compounds; Cell Line; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Fluorescence; Humans; Mice; Microscopy, Fluorescence; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; Structure-Activity Relationship; Thiazoles | 2014 |
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transplantation, Heterologous | 2014 |
An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade.
Topics: Adult; Aged; Antineoplastic Agents; Benzodioxoles; Cell Cycle; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Ovarian Neoplasms; Quinazolines; src-Family Kinases; Survival Analysis | 2014 |
Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis.
Topics: Actins; Animals; Benzodioxoles; Cell Differentiation; Cell Line; Cells, Cultured; Collagen; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Pulmonary Fibrosis; Quinazolines; src-Family Kinases; Transforming Growth Factor beta | 2014 |
Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chorionic Gonadotropin; Enzyme Inhibitors; Female; Gestational Trophoblastic Disease; Humans; Pregnancy; Pyrimidines; Quinazolines; src-Family Kinases | 2014 |
Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Surface Extensions; Chick Embryo; Cortactin; Female; Humans; Lung Neoplasms; Matrix Metalloproteinase 14; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Stem Cells; Phosphate-Binding Proteins; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; Transcellular Cell Migration | 2014 |
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms | 2014 |
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Benzodioxoles; Disease Models, Animal; Focal Adhesion Kinase 2; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Quinazolines; Signal Transduction | 2015 |
Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.
Topics: Aflatoxin B1; Benzodioxoles; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases | 2015 |
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Topics: Animals; Benzamides; Benzodioxoles; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Immunoblotting; Lung Neoplasms; MAP Kinase Kinase 1; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Genes, myc; Glucose; Humans; Mice; Protein Biosynthesis; Quinazolines; Receptors, Estrogen; src-Family Kinases | 2015 |
Effects of Src-kinase inhibition in cancer-induced bone pain.
Topics: Animals; Behavior, Animal; Benzodioxoles; Bone Neoplasms; Bone Remodeling; Bone Resorption; Cancer Pain; Disease Models, Animal; Hyperalgesia; Male; Neurons; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Spinal Cord; src-Family Kinases | 2016 |
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Topics: Administration, Oral; Animals; Benzodioxoles; Bone and Bones; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogenes; Quinazolines; src-Family Kinases | 2016 |
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Autophagy-Related Protein-1 Homolog; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Dasatinib; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases | 2017 |
Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Topics: Animals; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Topics: Alternative Splicing; Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Inhibitory Concentration 50; Lapatinib; Mammary Neoplasms, Experimental; Mice, Transgenic; Phenotype; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptor, ErbB-2; Signal Transduction; Time Factors | 2016 |
Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Benzodioxoles; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Mice, Inbred BALB C; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; src-Family Kinases; Trastuzumab | 2016 |
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 2; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Models, Biological; Ovarian Neoplasms; Phosphorylation; Quinazolines; Reproducibility of Results; RNA, Messenger; RNA, Small Interfering; Securin; src-Family Kinases | 2016 |
Cytochrome P450 Mediated Bioactivation of Saracatinib.
Topics: Activation, Metabolic; Animals; Benzodioxoles; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2016 |
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzodioxoles; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 3; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Survivin; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Benzodioxoles; Biomarkers; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Humans; Hyaluronan Receptors; Mice; Phosphorylation; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; src-Family Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis.
Topics: Animals; Anoikis; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Lymphatic Metastasis; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; src-Family Kinases | 2017 |
Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.
Topics: Arthritis, Rheumatoid; Benzodioxoles; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Fibroblasts; Humans; Organic Cation Transport Proteins; Protein-Tyrosine Kinases; Quinazolines; Symporters | 2017 |
Impaired activity of adherens junctions contributes to endothelial dilator dysfunction in ageing rat arteries.
Topics: Acetylcholine; Adherens Junctions; Aging; Animals; Antigens, CD; Arteries; Benzodioxoles; Cadherins; Endothelial Cells; Male; Phosphorylation; Quinazolines; Rats, Inbred F344; src-Family Kinases; Tyrosine; Vasodilator Agents | 2017 |
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Topics: Anilides; Animals; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dasatinib; Humans; Mice; Neurilemmoma; Neurofibromin 2; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Schwann Cells; src-Family Kinases; Xenograft Model Antitumor Assays | 2017 |
Src-dependent phosphorylation of μ-opioid receptor at Tyr
Topics: Animals; Behavior, Animal; Benzodioxoles; Body Weight; HEK293 Cells; Humans; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphine; Naloxone; Narcotic Antagonists; Phosphorylation; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, Opioid, mu; RNA Interference; RNA, Small Interfering; src-Family Kinases; Tyrosine | 2017 |
The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Topics: Animals; Benzodioxoles; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Movement; Neostriatum; Parkinson Disease; Phosphorylation; Protein Subunits; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2018 |
Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound.
Topics: Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Extracellular Matrix Proteins; High-Throughput Screening Assays; Humans; Lapatinib; Porphyrins; Quinazolines; Receptor, ErbB-2; Single-Cell Analysis; Small Molecule Libraries; Tumor Microenvironment; Verteporfin | 2017 |
Murine breast cancer mastectomy model that predicts patient outcomes for drug development.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Luminescent Measurements; Lung; Lung Neoplasms; Mammary Neoplasms, Experimental; Mastectomy, Radical; Mice, Inbred BALB C; Neoplasm Metastasis; Quinazolines | 2017 |
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzodioxoles; Maze Learning; Memantine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Nootropic Agents; Proto-Oncogene Proteins c-fyn; Quinazolines; Recognition, Psychology; Spatial Learning; Spatial Memory; Spatial Navigation; Synapses | 2018 |
Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Disease Models, Animal; Humans; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Membrane Microdomains; Membrane Potential, Mitochondrial; Mice; Neoplastic Stem Cells; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2018 |
miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; MicroRNAs; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2018 |
Tyrosine kinase Fyn promotes osteoarthritis by activating the β-catenin pathway.
Topics: Aging; Animals; Arthritis, Experimental; Benzodioxoles; beta Catenin; Cartilage, Articular; Cells, Cultured; Chondrocytes; Enzyme Inhibitors; Gene Knockout Techniques; Humans; Mice, Knockout; Molecular Targeted Therapy; Osteoarthritis; Proto-Oncogene Proteins c-fyn; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction | 2018 |
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Topics: Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL5; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Plasminogen Activator Inhibitor 1; Quinazolines; Receptor, ErbB-2; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling.
Topics: Animals; Benzodioxoles; Chromatography, Liquid; Humans; Imino Acids; Metabolome; Microsomes, Liver; Quinazolines; Quinones; Rats; Tandem Mass Spectrometry | 2018 |
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.
Topics: Antiviral Agents; Benzodioxoles; Cell Line; Cross Infection; Deoxycytidine; DNA Replication; Drug Discovery; Enzyme Inhibitors; Gemcitabine; Humans; Middle East Respiratory Syndrome Coronavirus; Quinazolines; Small Molecule Libraries; src-Family Kinases; Virus Replication | 2018 |
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Disease Models, Animal; Drug Carriers; Enzyme Inhibitors; Head and Neck Neoplasms; Mice; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Quinazolines; Snail Family Transcription Factors; src-Family Kinases; Vimentin | 2018 |
CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair.
Topics: Animals; Benzodioxoles; Biomarkers, Tumor; CD59 Antigens; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Disease-Free Survival; DNA Damage; DNA Repair; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; Radiation Tolerance; Transplantation, Heterologous | 2018 |
TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway.
Topics: Animals; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Protein Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Topics: Activin Receptors, Type I; Animals; Benzodioxoles; High-Throughput Screening Assays; Humans; Induced Pluripotent Stem Cells; Mice, SCID; Mice, Transgenic; Myositis Ossificans; Ossification, Heterotopic; Oxazoles; Pyrimidines; Quinazolines; Reproducibility of Results; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Urea | 2018 |
The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking.
Topics: Animals; Behavior, Animal; Benzodioxoles; Central Nervous System Depressants; Conditioning, Operant; Drug-Seeking Behavior; Ethanol; Extinction, Psychological; Locomotion; Mice; Neostriatum; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, N-Methyl-D-Aspartate; Self Administration | 2019 |
Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Immediate-Early Proteins; Mass Spectrometry; Mice, Inbred BALB C; Mice, Nude; Oncogenes; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Lyn is involved in host defense against S. agalactiae infection and BCR signaling in Nile tilapia (Oreochromis niloticus).
Topics: Animals; Benzodioxoles; Calcium; Cichlids; Disease Resistance; Fish Diseases; Fish Proteins; Head Kidney; Host-Pathogen Interactions; Leukocytes; Proto-Oncogene Proteins c-bcr; Quinazolines; Signal Transduction; src-Family Kinases; Streptococcus agalactiae; Up-Regulation | 2019 |
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.
Topics: Antineoplastic Agents; Benzodioxoles; Drug Resistance, Neoplasm; Guanine Nucleotide Exchange Factors; Humans; Melanoma; Melanoma, Cutaneous Malignant; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-vav; Quinazolines; Signal Transduction; Skin Neoplasms; src-Family Kinases; Vemurafenib | 2019 |
Synergistic effect of STAT3‑targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Glioblastoma; Mice, Inbred BALB C; Mice, Nude; Quinazolines; RNA, Small Interfering; RNAi Therapeutics; STAT3 Transcription Factor | 2019 |
Targeting c-Src Reverses Accelerated GPX-1 mRNA Decay in Chronic Obstructive Pulmonary Disease Airway Epithelial Cells.
Topics: Animals; Benzodioxoles; Enzyme Activation; Epithelial Cells; Epithelium; Female; Gene Expression Regulation; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Lung; Male; Mice; Proto-Oncogene Proteins pp60(c-src); Pulmonary Disease, Chronic Obstructive; Quinazolines; RNA Stability; Smoking | 2020 |
Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodioxoles; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Focal adhesion kinase and osmotic responses in ionocytes of Fundulus heteroclitus, a euryhaline teleost fish.
Topics: Animals; Benzodioxoles; Cystic Fibrosis Transmembrane Conductance Regulator; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Fundulidae; Ion Transport; Osmoregulation; Osmotic Pressure; Phosphorylation; Quinazolines; Tyrosine; Water-Electrolyte Balance | 2020 |
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 1; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Computational Biology; Disease Models, Animal; Drug Antagonism; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation; Humans; Liver Neoplasms; Mice; Oxaliplatin; Quinazolines; Signal Transduction; Wnt Proteins; Xenograft Model Antitumor Assays | 2020 |
Src Inhibition Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation and Decreasing Connetive Tissue Growth Factor.
Topics: Animals; Autophagy; Benzodioxoles; Cells, Cultured; Connective Tissue Growth Factor; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice, Inbred C57BL; Phosphorylation; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thioacetamide; Transforming Growth Factor beta; Up-Regulation | 2020 |
Biophysical and computational view on the
Topics: Antineoplastic Agents; Benzodioxoles; Binding Sites; Circular Dichroism; Humans; Molecular Docking Simulation; Protein Binding; Quinazolines; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics | 2021 |
Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Topics: Aged, 80 and over; Animals; Benzodioxoles; Brain Concussion; Enzyme Inhibitors; Humans; Male; Memory Disorders; Mice; Mice, Transgenic; Protein Aggregates; Protein Aggregation, Pathological; Proto-Oncogene Proteins c-fyn; Quinazolines; Synapses; tau Proteins; Tauopathies | 2020 |
Anti-allergic effect of the Src family kinase inhibitor saracatinib.
Topics: Anaphylaxis; Animals; Anti-Allergic Agents; Benzodioxoles; Cell Line; Cell Survival; Disease Models, Animal; Enzyme Inhibitors; Immunoglobulin E; Male; Mast Cells; Mice; Mice, Hairless; Phosphorylation; Quinazolines; Rats; src-Family Kinases | 2020 |
Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Autophagy-Related Protein 5; Benzodioxoles; Caspase 7; Cell Proliferation; Enzyme Inhibitors; Fungal Proteins; Ganoderma; Humans; Immunologic Factors; Lung Neoplasms; Mice; Quinazolines; src-Family Kinases; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2021 |
Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Injections, Intraventricular; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Quinazolines; Receptor, Notch1; Signal Transduction; SOXB1 Transcription Factors; src-Family Kinases; Stereotaxic Techniques; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Apoptosis; Benzodioxoles; Cell Survival; Female; Humans; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Naphthyridines; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinazolines; RNA Interference; RNA Stability; RNA-Binding Proteins; RNA, Messenger; RNA, Small Interfering; Transplantation, Heterologous | 2021 |
ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib.
Topics: Animals; Benzodioxoles; Induced Pluripotent Stem Cells; Mice; Myositis Ossificans; Quinazolines; Signal Transduction; Smad1 Protein; Smad5 Protein | 2021 |
Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice.
Topics: Animals; Benzodioxoles; Cognition; Cognitive Dysfunction; Enzyme Inhibitors; Hippocampus; Male; Mice; Mice, Inbred C57BL; Neurons; Proto-Oncogene Proteins c-fyn; Quinazolines; Status Epilepticus | 2021 |
Proteasome regulation by reversible tyrosine phosphorylation at the membrane.
Topics: Acetylation; Animals; Benzodioxoles; Cell Membrane; Cytoplasm; Heterografts; Humans; Lung Neoplasms; Mice; Mutation; Phosphorylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Quinazolines; Tyrosine | 2021 |
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.
Topics: Activin Receptors, Type I; Animals; Benzodioxoles; Bone Morphogenetic Proteins; Drug Evaluation, Preclinical; Gene Knock-In Techniques; Mice; Mice, Transgenic; Muscles; Myositis Ossificans; Ossification, Heterotopic; Quinazolines; Zebrafish | 2021 |
Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.
Topics: Animals; Benzodioxoles; Disease Models, Animal; Electroencephalography; Enzyme Inhibitors; Epilepsy, Temporal Lobe; Inflammation Mediators; Kainic Acid; Male; Proto-Oncogene Proteins c-fyn; Quinazolines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Telemetry | 2021 |
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Cycle; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation | 2021 |
Attenuation of cartilage pathogenesis in osteoarthritis by blocking the phosphorylation of tyrosine kinase Fyn to β-catenin, AZD0530.
Topics: Animals; Benzodioxoles; beta Catenin; Cartilage, Articular; Cells, Cultured; Chondrocytes; Osteoarthritis; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-fyn; Quinazolines; Rats; Wnt Signaling Pathway | 2022 |
Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Boron Compounds; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; Gene Knockout Techniques; Glycine; GTPase-Activating Proteins; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice; Mutagenesis, Site-Directed; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2021 |
Evaluation of the Efficacy of Saracatinib-Loaded Nanoparticles in Lymphatic Metastases of HNSCC with the Aid of Bioluminescence Imaging.
Topics: Animals; Benzodioxoles; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Lymphatic Metastasis; Mice; Nanoparticles; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2022 |
Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis).
Topics: Antineoplastic Agents; Benzodioxoles; Humans; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; src-Family Kinases | 2022 |